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We describe a 66-year-old woman with therapy-refrac-
tory cryoglobulinemia treated with rituximab, plasmaphere-
sis, and steroids; a case of fatal meningoencephalitis
caused by Acanthamoeba spp. then developed. Such
infections are rare and show an unusually rapid course
(possibly related to rituximab).
I
nfection with Acanthamoeba, a free-living ameba, is a
rare cause of slowly progressive granulomatous amebic
encephalitis (GAE) in immunocompromised patients. This
form of encephalitis is almost universally progressive and
fatal, typically within 2 months of symptom onset (1). We
describe a patient with cryoglobulinemia refractory to stan-
dard therapy who died of GAE after receiving rituximab.
Rituximab is a monoclonal antibody directed against
CD20, a surface antigen expressed in cells of B-lympho-
cyte lineage. It was developed for treatment of B-cell lym-
phomas. Recently, therapy with rituximab has been
extended to a variety of autoimmune diseases in which B
cells have been thought to play a role. The drug substan-
tially depletes normal B cells from the peripheral blood
and its use leads to a prolonged period of humoral immune
dysfunction (2).
The Case
In March 2005, a 66-year-old woman was referred to
our hospital because of status epilepticus. A diagnosis of
hepatitis C had been made in 2003. In January 2005, hep-
atitis C–related cryoglobulinemic vasculitis with cuta-
neous and renal involvement developed. The
cryoprecipitate contained 586 mg/L of immunoglobulin G
(IgG) and 517 mg/Lof IgM (normal <10 mg/L). Treatment
with prednisolone (1 g intravenously for 3 days, followed
by 64 mg orally once a day until day 31) was started in
January 2005 (day 1). Despite this treatment, the vasculitis
worsened. Plasmapheresis was started on day 10 (8 ses-
sions) and resumed on day 39 (10 sessions). The patient’s
cryocrit decreased. The prednisolone dose was tapered on
day 31 to 16 mg. Increasing palpable purpura on the lower
legs was observed on day 46. The decision was made to
start rituximab infusions (375 mg/m2), which she received
starting on day 48 on a weekly basis; she received 2 infu-
sions. On day 55, she had a seizure and was transferred to
the intensive care unit. She was deeply comatose with a
Glasgow coma score of 4/15. Vital signs were normal.
Magnetic resonance imaging showed a T2 hyperintense
lesion in the right frontal region of the brain (Figure 1). At
that time, the lesion was believed to be related to the cryo-
globulinemia. Examination of cerebrospinal fluid (CSF)
showed a protein level of 228 mg/dL, a glucose level of 53
mg/dL, and 13 lymphocytes/µL. Culture of blood and CSF,
serologic tests, and PCR did not show any fungi, viruses,
or bacteria. The patient remained in a nonconvulsive status
epilepticus despite combination anticonvulsive therapy.
She died on day 61.
Postmortem examination showed signs of glomeru-
lonephritis, liver fibrosis, and moderate signs of myocardi-
tis. A formalin-fixed, 1,378-g brain specimen showed no
discoloration or meningeal opacification throughout most
parts of the brain. Small lacerations were visible in the
pedunculus cerebri superior and both hemispheres of the
cerebellum. No obvious intraparenchymal bleeding was
present. Hematoxylin and eosin–stained sections showed a
necrotizing hemorrhagic meningoencephalitis and adja-
cent recent infarctions. Numerous trophozoites and
Acanthamoeba cysts were observed within necrotic areas
and overlying meninges. Trophozoites were predominant-
ly perivascularly located in nonnecrotic areas and cysts
were detectable within blood vessel walls (Figure 2A). For
immunohistochemical analysis, 3-µm–thick sections of
paraffin-embedded brain tissue were cut and stained with
an antibody to Acanthamoeba spp. (from rabbits immu-
nized with Acanthamoeba genotype T4) at a dilution of
1:2,000. Antigen retrieval was performed by heating sec-
tions in 0.01 mol/L citrate buffer (pH 6.0) for 60 minutes.
ChemMate kit K5001 (Dako, Glostrup, Denmark) was
used for immunostaining (Figure 2B).
We conducted a PCR for detection of Acanthamoeba
spp., Balamuthia mandrillaris, and Naegleria fowleri in
brain tissue and CSF by using JDP primers for a diagnos-
tic small subunit rDNA fragment as previously described
(3). Acanthamoeba DNA was detected in brain tissue but
not in CSF. Typing of the Acanthamoeba strain by
sequencing the amplified partial small subunit rRNA gene
region (ASA.S1) with primer 892c as previously described
(4) showed that the strain had genotype T4. The sequenced
region is identical to that found in the European Molecular
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Conclusions
We report a rapidly fatal case of GAE in a woman
with cryoglobulinemia treated with rituximab. GAE is a
rare but often lethal subacute cause of meningoencephali-
tis, typically occurring in immunocompromised patients.
Acanthamoeba spp. are the most common free-living ame-
bae, are ubiquitous in the environment, and are widespread
in water and soil. Low-level antibody titers are found in
>50% of asymptomatic patients (5,6). More than 20
species of these amebae have been described (1). In addi-
tion to causing keratitis after use of contact lenses,
Acanthamoeba spp. are responsible for meningoencephali-
tis in chronically ill, debilitated patients; in patients taking
immunosuppressive drugs or receiving chemotherapy; and
in patients with AIDS (1). GAE shows a chronic course
with atypical symptoms of low-grade fever, encephalopa-
thy with cognitive abnormalities, headache, and seizures.
This disease is rarely identified in patients before death.
CSF analysis shows moderate pleiocytosis, but it rarely
contributes to the diagnosis because amebae are generally
not found in the CSF. Recently, detection of serum anti-
bodies was successfully used in screening for free-living
amebae in patients in California with encephalitis (7).
However, this process proved to be of value mainly for
identifying B. mandrillaris, another free-living ameba.
Evidence of Acanthamoeba infection was recently
found by PCR in brain tissue of a patient with lupus, even
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Figure 1. Magnetic resonance image of the patient’s brain after the
first seizure showing a hemorrhagic lesion in the right frontal lobe.
Figure 2. A) Cysts in a vessel wall (arrows) of the patient (hema-
toxylin and eosin stain, magnification ×250). Inset shows a cyst at
higher magnification (hematoxylin and eosin stain, magnification
×800). B) Immunohistochemical staining with antibody to
Acanthamoeba cysts within vessel walls (magnification ×250).
C) Polyacrylamide gel electrophoresis of PCR products for
Acanthamoeba spp., Naegleria spp., and Balamuthia mandrillaris
using JDP primers for a diagnostic small subunit rDNA fragment.
M, molecular mass marker; Pat, patient; Neg, negative control;
Pos, positive control. without isolating the ameba (8). A PCR with tissue and
CSF is potentially useful in clinical laboratories in identi-
fying the cause of meningoencephalitis without the need
for specific antibodies.
Because the patient’s cryoglobulinemia was poorly
controlled, we decided to begin treating our patient’s con-
dition with rituximab. This monoclonal antibody has been
shown to be effective in treating cryoglobulinemia resist-
ant to standard therapies with corticosteroids and plasma-
pheresis (9). This antibody against the CD20 receptor on
the surface of the B lymphocytes destroys these cells by
mechanisms involving complement-mediated and anti-
body-dependent cytotoxicity (10). Levels of B cells remain
low for 2 to 6 months, which leads to long-term humoral
immune dysfunction. Serious viral infections such as ery-
throcyte aplasia caused by parvovirus B19, fatal hepatitis
B, and cytomegalovirus and varicella-zoster virus infec-
tions have been reported after administration of rituximab
(11–14). The fact that our patient died of Acanthamoeba
encephalitis is striking because rituximab is believed to
interfere with humoral immunity, which is not known to
play a major role against free-living amebic infections. 
We identified a temporal relationship between the
weekly rituximab treatments and meningoencephalitis.
Although the patient received corticosteroids and under-
went plasmapheresis, GAE developed only after rituximab
infusions had begun and the steroid dose was being
tapered. It is not clear whether rituximab is the only agent
responsible for the GAE, or what contributions were made
by the earlier treatments the patient received. We could not
identify the source of infection in this patient. In particular,
we found no evidence for nosocomial acquisition. No
other patient had a diagnosis of Acanthamoeba brain infec-
tion, and no one receiving rituximab had unexplained
meningoencephalitis in 2005 in our institution. Our
hypothesis is that Acanthamoeba spp. were already present
in the brain at the time of the first rituximab infusion, but
that rituximab may have precipitated the unusually rapid
course of the encephalitis.
Rituximab is obtaining widespread use in hematolog-
ic and autoimmune diseases as an adjuvant therapy. The
full spectrum of opportunistic infections in patients receiv-
ing combinations of immunosuppressive regimens remains
to be elucidated and warrants vigilance.
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